EA201690159A1 - Способы и композиции для лечения рака - Google Patents

Способы и композиции для лечения рака

Info

Publication number
EA201690159A1
EA201690159A1 EA201690159A EA201690159A EA201690159A1 EA 201690159 A1 EA201690159 A1 EA 201690159A1 EA 201690159 A EA201690159 A EA 201690159A EA 201690159 A EA201690159 A EA 201690159A EA 201690159 A1 EA201690159 A1 EA 201690159A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
methods
cancer treatment
cancer
treatment
Prior art date
Application number
EA201690159A
Other languages
English (en)
Other versions
EA035463B1 (ru
Inventor
Лаура Соусек
Мари-Эв Болье
Original Assignee
Фундасио Привада Институт Д'Инвестигасио Онколохика Де Валь Хеброн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фундасио Привада Институт Д'Инвестигасио Онколохика Де Валь Хеброн filed Critical Фундасио Привада Институт Д'Инвестигасио Онколохика Де Валь Хеброн
Publication of EA201690159A1 publication Critical patent/EA201690159A1/ru
Publication of EA035463B1 publication Critical patent/EA035463B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Изобретение относится к доминантно-негативному мутанту Мус, называемому Omomyc, для применения в медицине и для применения в профилактике и/или лечении рака. Изобретение также относится к слитому белку, содержащему Omomyc, и к его фармацевтической композиции и к применению в медицине, и в частности, для лечения рака.
EA201690159A 2013-05-07 2014-05-07 Способы и композиции для лечения рака EA035463B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20130382167 EP2801370A1 (en) 2013-05-07 2013-05-07 Methods and compositions for the treatment of cancer
PCT/EP2014/059315 WO2014180889A1 (en) 2013-05-07 2014-05-07 Methods and compositions for the treatment of cancer

Publications (2)

Publication Number Publication Date
EA201690159A1 true EA201690159A1 (ru) 2016-05-31
EA035463B1 EA035463B1 (ru) 2020-06-19

Family

ID=48366303

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202090683A EA202090683A3 (ru) 2013-05-07 2014-05-07 Способы и композиции для лечения рака
EA201690159A EA035463B1 (ru) 2013-05-07 2014-05-07 Способы и композиции для лечения рака

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA202090683A EA202090683A3 (ru) 2013-05-07 2014-05-07 Способы и композиции для лечения рака

Country Status (25)

Country Link
US (2) US10370434B2 (ru)
EP (4) EP2801370A1 (ru)
JP (2) JP6722103B2 (ru)
KR (1) KR102324116B1 (ru)
CN (1) CN105378084B (ru)
AU (1) AU2014264642B2 (ru)
BR (2) BR122020017819B1 (ru)
CA (1) CA2911863A1 (ru)
CY (1) CY1121849T1 (ru)
DK (1) DK2994533T3 (ru)
EA (2) EA202090683A3 (ru)
ES (1) ES2733515T3 (ru)
HK (2) HK1219756A1 (ru)
HR (1) HRP20191330T1 (ru)
HU (1) HUE045615T2 (ru)
IL (2) IL242483B (ru)
LT (1) LT2994533T (ru)
ME (1) ME03509B (ru)
MX (1) MX370792B (ru)
PL (1) PL2994533T3 (ru)
PT (1) PT2994533T (ru)
RS (1) RS59276B1 (ru)
SG (2) SG10201709101VA (ru)
SI (1) SI2994533T1 (ru)
WO (1) WO2014180889A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2801370A1 (en) 2013-05-07 2014-11-12 Fundació Privada Institut d'Investigació Oncològica de Vall Hebron Methods and compositions for the treatment of cancer
US10654894B2 (en) * 2016-02-03 2020-05-19 Keenesaw State University Research And Service Foundation, Inc. Methods for delivering cargo into a cell by using signal molecules as cell penetration agents
WO2017190061A1 (en) * 2016-04-29 2017-11-02 The University Of Chicago Synthetic dna binding domain peptides and uses thereof
EP3269734A1 (en) * 2016-07-15 2018-01-17 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Methods and compositions for the treatment of cancer
CN106591335A (zh) * 2016-11-08 2017-04-26 安徽省农业科学院水稻研究所 一种密码子植物化改造的LbCpf1基因及其应用
EP3678679A1 (en) * 2017-09-08 2020-07-15 IDP Discovery Pharma, S.L. New treatments of multiple myeloma
WO2019108134A1 (en) * 2017-11-29 2019-06-06 Agency For Science, Technology And Research Chimeric molecule for targeting c-myc in cells
KR20200143416A (ko) * 2018-04-09 2020-12-23 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 엑소좀을 사용하는 종양 유전자의 치료학적 표적화
US20220088221A1 (en) * 2019-01-12 2022-03-24 The Methodist Hospital Self-assembled peptide nanoparticle and use thereof
CA3133155A1 (en) * 2019-03-19 2020-09-24 Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron Combination therapy for the treatment for cancer
TWI829893B (zh) * 2019-03-19 2024-01-21 瓦爾希伯倫私人腫瘤研究基金會 診斷肺癌的方法
KR102221227B1 (ko) 2019-05-07 2021-03-03 김영화 공급자 연동과 다국어 지원 기능을 구비한 쇼핑몰 플랫폼 제공 장치 및 그 방법
US20220307013A1 (en) * 2019-08-30 2022-09-29 The Regents Of The University Of California Gene fragment overexpression screening methodologies, and uses thereof
CN115925975A (zh) * 2022-08-03 2023-04-07 山东大学 一种靶向肿瘤干细胞的car-mφ体内外编辑制备方法以及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
ATE12348T1 (de) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US5322801A (en) 1990-04-19 1994-06-21 The General Hospital Corporation Protein partner screening assays and uses thereof
EP0633933A1 (en) 1992-03-23 1995-01-18 Imperial Cancer Research Technology Limited Leucine zippers
EP1342781A1 (en) * 2002-03-09 2003-09-10 ARTEMIS Pharmaceuticals GmbH Recombinase fusion protein with enhanced cellular uptake
GB0413730D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
EP2477985B1 (en) * 2009-09-15 2018-11-07 BlueLink Pharmaceuticals, Inc. Crlx101 for use in the treatment of cancer
DE102009052866A1 (de) 2009-11-13 2011-05-19 Bizerba Gmbh & Co. Kg Schneidemaschine
US9155724B2 (en) 2010-02-05 2015-10-13 Whitehead Institute For Biomedical Research Combination methods for treatment of disease
AU2011267078B2 (en) * 2010-06-14 2014-09-25 F. Hoffmann-La Roche Ag Cell-penetrating peptides and uses therof
WO2013063560A2 (en) * 2011-10-27 2013-05-02 New York University INHIBITION OF c-MYC UBIQUITINATION TO PREVENT CANCER INITIATION AND PROGRESSION
EP2801370A1 (en) 2013-05-07 2014-11-12 Fundació Privada Institut d'Investigació Oncològica de Vall Hebron Methods and compositions for the treatment of cancer

Also Published As

Publication number Publication date
AU2014264642B2 (en) 2020-09-17
CN105378084A (zh) 2016-03-02
EP3545966A1 (en) 2019-10-02
DK2994533T3 (da) 2019-07-01
US11339205B2 (en) 2022-05-24
JP6790148B2 (ja) 2020-11-25
PT2994533T (pt) 2019-08-05
SI2994533T1 (sl) 2019-09-30
JP2016520056A (ja) 2016-07-11
KR20160013058A (ko) 2016-02-03
EP2994533B1 (en) 2019-05-01
BR112015028115A2 (pt) 2017-10-17
AU2014264642A1 (en) 2015-11-19
EA202090683A3 (ru) 2020-09-30
HUE045615T2 (hu) 2020-01-28
CY1121849T1 (el) 2020-07-31
EP2994533A1 (en) 2016-03-16
EP2801370A1 (en) 2014-11-12
HK1219756A1 (zh) 2017-04-13
IL273090B (en) 2022-06-01
WO2014180889A1 (en) 2014-11-13
MX370792B (es) 2020-01-08
ME03509B (me) 2020-04-20
IL273090A (en) 2020-04-30
BR112015028115B1 (pt) 2023-11-21
SG10201709101VA (en) 2017-12-28
BR122020017819B1 (pt) 2023-11-21
US20160122415A1 (en) 2016-05-05
EA035463B1 (ru) 2020-06-19
IL242483B (en) 2020-03-31
HK1251494A1 (zh) 2019-02-01
RS59276B1 (sr) 2019-10-31
ES2733515T3 (es) 2019-11-29
US10370434B2 (en) 2019-08-06
JP2019147792A (ja) 2019-09-05
CA2911863A1 (en) 2014-11-13
JP6722103B2 (ja) 2020-07-15
US20190382468A1 (en) 2019-12-19
MX2015015518A (es) 2016-07-21
KR102324116B1 (ko) 2021-11-11
WO2014180889A8 (en) 2015-06-18
PL2994533T3 (pl) 2020-03-31
SG11201509131VA (en) 2015-12-30
HRP20191330T1 (hr) 2019-10-18
LT2994533T (lt) 2019-08-12
EA202090683A2 (ru) 2020-06-30
EP3338789A1 (en) 2018-06-27
CN105378084B (zh) 2019-07-05

Similar Documents

Publication Publication Date Title
EA201690159A1 (ru) Способы и композиции для лечения рака
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
MX2018007703A (es) Inhibidores de la interaccion de menina-linaje leucemico mixto.
EA201792047A1 (ru) Новые соединения
EA201691059A1 (ru) Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201592143A1 (ru) Новые бициклические ингибиторы бромодомена
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
PH12019501405A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
CR20160353A (es) Inhibidor de proteína de transferencia del éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden el inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
EA201790609A1 (ru) Макроциклические ингибиторы rip2-киназы